Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Go back to Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 37.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.31 | 52 Week High | $5.17 | |||
| Open | $37.31 | 52 Week Low | $0.94 | |||
| Day High | $37.31 | P/E | N/A | |||
| Day Low | $37.31 | EPS | $0.00 | |||
| Volume | 2,994 | |||||
